M2-polarized tumor-associated macrophage (M2-TAM)

M2-polarized tumor-associated macrophages (M2-TAMs) are a distinct population of immune cells within the tumor microenvironment that have been co-opted by the cancer to support its growth and progression. Unlike M1 macrophages, which are pro-inflammatory and anti-tumorigenic, M2-TAMs exhibit an 'alternatively activated' phenotype characterized by the secretion of immunosuppressive cytokines like IL-10 and TGF-beta, the promotion of angiogenesis through VEGF, and the remodeling of the extracellular matrix to facilitate metastasis. They play a critical role in shielding the tumor from the host's adaptive immune system by inhibiting T-cell activity and recruiting regulatory T-cells. In clinical oncology, M2-TAMs are significant therapeutic targets because their high density in tumors is often correlated with poor prognosis and resistance to conventional therapies, including checkpoint inhibitors. Current pharmacological approaches focus on either depleting these cells by blocking survival signals such as the Colony Stimulating Factor 1 Receptor (CSF1R) or 're-educating' them toward an M1 phenotype using agonists for Toll-like receptors (TLRs) or STING. While promising, targeting M2-TAMs presents challenges, including the need for high specificity to avoid disrupting the essential homeostatic functions of macrophages in healthy tissues like the liver and lungs.

Other names

Alternatively activated macrophageM2 macrophageTumor-associated macrophageTAMPro-tumorigenic macrophage

Therapeutic strategies targeting M2-TAMs include depletion of the macrophage population (e.g., via CSF1R inhibition), inhibition of macrophage recruitment to the tumor microenvironment (e.g., via CCL2/CCR2 blockade), and functional reprogramming from a pro-tumorigenic M2 phenotype to a pro-inflammatory, anti-tumorigenic M1 phenotype.